Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1831 - A retrospective study of the management of metastatic renal cell carcinoma brain tumors

Date

10 Sep 2017

Session

Poster display session

Presenters

Guillaume Klausner

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

G. Klausner1, I. Troussier1, G. Malouf2, L. Feuvret1, J. Jacob1, J. Simon1, C.H. Canova1, I. Lamproglou3, P. Borius3, C. Valery3, P. Cornu3, M. Rouprêt4, J. Mazeron1, J. Spano2, P. Maingon1

Author affiliations

  • 1 Radiotherapy, Pitié-Salpêtrière Hospital, 75651 - Paris/FR
  • 2 Medical Oncology, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
  • 3 Neurosurgery, Pitié-Salpêtrière Hospital, 75651 - Paris/FR
  • 4 Urology, Pitié-Salpêtrière Hospital, 75651 - Paris/FR
More

Resources

Abstract 1831

Background

The purpose of this retrospective monocentric review was to evaluate the different techniques of stereotactic radiosurgery in the management of brain tumors from renal cell carcinoma (RCC).

Methods

From 2005 to 2015, 120 patients, with a total of 398 brain metastasis of RCC, were treated at least by stereotactic radiosurgery. Median age was 58 years (31–82). Median Karnofski performance status was 90 (50-100). One hundred ten tumors (92%) were clear cell carcinoma. Ninety-nine patients (82.5%) have undergone nephrectomy. The median time between the diagnosis of RCC and the first brain metastasis was 24 months (0-252).

Results

The median number of tumors per patient was 2 (1-46). The median diameter of the tumors was 13 mm (1-60). For the 120 patients, 222 procedures of treatment were recorded and 187 stereotactic irradiations were reviewed. Sixty-one patients (226 metastasis) were treated by Gamma Knife Surgery (GKS) and received a median dose on the 50% prescription isodose of 18 Gy (14-22). The minimal and maximal median dose was respectively 18.4 Gy (12.5-40.1) and 36 Gy (23.3-51.2). Sixty-three patients (136 metastasis) were treated by linear accelerator (photon 10 MV). The minimal (isodose 70%) and maximal (isocentre) median dose were respectively 16 Gy (9.8-25.8) and 20.3 Gy (15.3-33.74). The median disease-free survival time is 5.5 months (0-252). The median survival time between the first brain metastasis diagnosis and death is 13.5 months (0.5-147). The tumor growth control rates at 3, 6, 12 months are respectively 86%, 62%, 36%. Following the 187 stereotactic irradiations, 95 (51%) cerebral disease progressions are recorded, after a median time of 5 months (1-81); 81 progressions (85%) are due to new lesions and 25 (26%) due to local failures. Analyses of prognostic factors related to survival are still in progress.

Conclusions

Stereotactic radiosurgery is associated with a high local control of brain metastasis from RCC without whole brain radiotherapy. The two described modalities present different characteristics whose advantages will be further discussed with the assessment of prognostic and predictive factors of local control.

Clinical trial identification

Legal entity responsible for the study

Assistance Publique des Hôpitaux de Paris (APHP)

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.